Breast Cancer and Bone Metastasis: A Critical Analysis of Traditional and Modern Treatment Strategies

Authors

  • Shoxista Rustamjon kizi Erkinova Andijan State Medical Institute (1st-year master’s student in oncology) Author
  • Uktamxon Akmalkhon kizi Adhamjonova Andijan State Medical Institute (1st-year master’s student in oncology) Author
  • Gulnozakhon Shuhratbek kizi Abdivokhobova Andijan State Medical Institute (1st-year master’s student in oncology) Author
  • Soxibaxon Sadik qizi Yakubbekova Andijan State Medical Institute (Associate Professor, Department of Oncology) Author

Keywords:

breast cancer, bone metastasis, osteolytic lesions, denosumab, zoledronic acid, RANKL, targeted therapy, skeletal-related events, precision medicine, immunotherapy

Abstract

Breast cancer represents one of the most prevalent malignancies worldwide, with bone metastasis occurring in approximately 65–75% of patients with advanced-stage disease. The colonisation of the skeletal system by tumour cells precipitates a debilitating cycle of osteolytic and osteoblastic destruction, significantly compromising patient survival, functional capacity, and quality of life. This review critically analyses and compares the therapeutic landscape governing breast cancer–related bone metastasis, from established modalities—including chemotherapy, endocrine therapy, and external beam radiotherapy—to contemporary advances in targeted therapy, bone-modifying agents, immunotherapy, and precision medicine.

NINE muqovasi

Downloads

Published

2026-11-02

Issue

Vol. 3 No. 11 (2026): November 2026

Section

Articles

License

Copyright (c) 2026 The author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Breast Cancer and Bone Metastasis: A Critical Analysis of Traditional and Modern Treatment Strategies. (2026). New Innovations in National Education, 3(11). https://reandpub.uz/nine/article/view/1381

References

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., ... & Loi, S. (2019). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, 30(3), 397–404. https://doi.org/10.1093/annonc/mdy517

Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834–846. https://doi.org/10.1038/nrc2256

Ahern, E., Smyth, M. J., Dougall, W. C., & Teng, M. W. (2018). Roles of the RANKL–RANK axis in antitumour immunity—implications for therapy. Nature Reviews Clinical Oncology, 15(11), 676–693. https://doi.org/10.1038/s41571-018-0095-y

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., ... & Juric, D. (2019). Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. New England Journal of Medicine, 380(20), 1929–1940. https://doi.org/10.1056/NEJMoa1813904

Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., ... & Kalinsky, K. (2019). Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. New England Journal of Medicine, 380(8), 741–751. https://doi.org/10.1056/NEJMoa1814213

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., ... & Hortobagyi, G. N. (2012). Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. New England Journal of Medicine, 366(6), 520–529. https://doi.org/10.1056/NEJMoa1109653

Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 9(7), 463–475. https://doi.org/10.1038/nrc2656

Baum, R. P., Kulkarni, H. R., Singh, A., Kaemmerer, D., Mueller, D., Prasad, V., ... & Schuchardt, C. (2020). Results and adverse events of personalised peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget, 9(29), 16932–16950. https://doi.org/10.18632/oncotarget.24524

Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., ... & Aerts, H. J. (2019). Artificial intelligence in cancer imaging: Clinical challenges and applications. CA: A Cancer Journal for Clinicians, 69(2), 127–157. https://doi.org/10.3322/caac.21552

Bidard, F. C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., ... & Cristofanilli, M. (2022). Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomised phase III EMERALD trial. Journal of Clinical Oncology, 40(28), 3246–3256. https://doi.org/10.1200/JCO.22.00338

Bonneterre, J., Thürlimann, B., Robertson, J. F., Krzakowski, M., Mauriac, L., Koralewski, P., ... & Buzdar, A. (2001). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomised group efficacy and tolerability study. Journal of Clinical Oncology, 18(22), 3748–3757. https://doi.org/10.1200/JCO.2000.18.22.3748

Booth, C. M., Karim, S., & Mackillop, W. J. (2012). Real-world data: Towards achieving the achievable in cancer care. Nature Reviews Clinical Oncology, 16(5), 312–325. https://doi.org/10.1038/s41571-019-0167-7

Brufsky, A. M., Fontaine-Rothe, P., Octavia, D., & Perez, J. (2012). OPTIMIZE-2: A randomised open-label phase III trial assessing the long-term duration of zoledronic acid in breast cancer patients. Journal of Clinical Oncology, 30(15 suppl), LBA512. https://doi.org/10.1200/JCO.2012.30.15_suppl.LBA512

Burger, J. A., & Kipps, T. J. (2006). CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107(5), 1761–1767. https://doi.org/10.1182/blood-2005-08-3182

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., ... & Winer, E. P. (2018). 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 29(8), 1634–1657. https://doi.org/10.1093/annonc/mdy192

Chow, E., Harris, K., Fan, G., Tsao, M., & Sze, W. M. (2007). Palliative radiotherapy trials for bone metastases: A systematic review. Journal of Clinical Oncology, 25(11), 1423–1436. https://doi.org/10.1200/JCO.2006.09.5281

Cleeland, C. S., Body, J. J., Stopeck, A., von Moos, R., Fallowfield, L., Mathias, S. D., ... & Brufsky, A. (2012). Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomised, double-blind study of denosumab and zoledronic acid. Cancer, 119(4), 832–838. https://doi.org/10.1002/cncr.27789

Coleman, R. E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research, 12(20), 6243s–6249s. https://doi.org/10.1158/1078-0432.CCR-06-0931

Coleman, R., Cameron, D., Dodwell, D., Bell, R., Wilson, C., Rathbone, E., ... & Brown, J. (2011). Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) trial. The Lancet Oncology, 15(9), 997–1006. https://doi.org/10.1016/S1470-2045(14)70302-X